Tags

Type your tag names separated by a space and hit enter

Biochemical markers of insulin-like growth factor-I misuse in athletes: the response of serum IGF-I, procollagen type III amino-terminal propeptide, and the GH-2000 score to the administration of rhIGF-I/rhIGF binding protein-3 complex.
J Clin Endocrinol Metab. 2014 Jun; 99(6):2259-68.JC

Abstract

CONTEXT

The GH-2000 and GH-2004 research groups developed a method for detecting GH misuse in athletes based on the measurement of serum IGF-I and procollagen type III amino-terminal propeptide (P-III-NP). There are reports that IGF-I is also misused by athletes, but currently there is no internationally recognized test designed to detect recombinant human IGF-I misuse.

OBJECTIVE

The objective of the study was to examine the response of serum IGF-I, P-III-NP, and the GH-2000 score to recombinant human (rh) IGF-I/rhIGF binding protein-3 (IGFBP-3) administration in recreational athletes.

DESIGN AND SETTING

This was a randomized, double-blind, placebo-controlled rhIGF-I/rhIGFBP-3 administration study at Southampton General Hospital (Southampton, United Kingdom).

PARTICIPANTS

Fifty-six recreational athletes (26 women, 30 men) participated in the study.

INTERVENTION

Participants were randomized to treatment with low-dose (30 mg/d) or high-dose (60 mg/d) rhIGF-I/rhIGFBP-3 complex or placebo for 28 days. Blood was collected throughout the drug administration and washout periods. Serum IGF-I and P-III-NP were measured using commercial immunoassays and GH-2000 scores were calculated.

RESULTS

IGF-I, P-III-NP, and the GH-2000 score rose in response to both low- and high-dose rhIGF-I/rhIGFBP-3 administration. The relative maximum response of IGF-I (approximately 4-fold increase in women and men) was greater than that of P-III-NP (40%-50% increase in women, 35%-50% increase in men). The GH-2000 formulae, which incorporate IGF-I and P-III-NP results, detected up to 61% of women and 80% of men in the rhIGF-I/rhIGFBP-3 groups but, using IGF-I concentrations alone, the sensitivity increased to 94% in both women and men during the administration period.

CONCLUSIONS

The rise in P-III-NP after rhIGF-I/rhIGFBP-3 administration is small compared with that after rhGH administration. Although rhIGF-I/rhIGFBP-3 administration can be detected using the GH-2000 score method, a test based on serum IGF-I alone provides better sensitivity.

Authors+Show Affiliations

Human Development and Health Academic Unit (N.G., I.E.-M., S.P.N., M.F., P.H.S., R.I.G.H.), Faculty of Medicine, University of Southampton, Southampton SO16 6YD, United Kingdom; Drug Control Centre (C.B., D.A.C.), Department of Forensic and Analytical Science, King's College London, London SE1 9NH, United Kingdom; and School of Mathematics, Statistics, and Actuarial Science (E.E.B.), University of Kent, Canterbury, Kent CT2 7NZ, United Kingdom.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

24606087

Citation

Guha, Nishan, et al. "Biochemical Markers of Insulin-like Growth factor-I Misuse in Athletes: the Response of Serum IGF-I, Procollagen Type III Amino-terminal Propeptide, and the GH-2000 Score to the Administration of rhIGF-I/rhIGF Binding Protein-3 Complex." The Journal of Clinical Endocrinology and Metabolism, vol. 99, no. 6, 2014, pp. 2259-68.
Guha N, Erotokritou-Mulligan I, Bartlett C, et al. Biochemical markers of insulin-like growth factor-I misuse in athletes: the response of serum IGF-I, procollagen type III amino-terminal propeptide, and the GH-2000 score to the administration of rhIGF-I/rhIGF binding protein-3 complex. J Clin Endocrinol Metab. 2014;99(6):2259-68.
Guha, N., Erotokritou-Mulligan, I., Bartlett, C., Nevitt, S. P., Francis, M., Bassett, E. E., Cowan, D. A., Sönksen, P. H., & Holt, R. I. (2014). Biochemical markers of insulin-like growth factor-I misuse in athletes: the response of serum IGF-I, procollagen type III amino-terminal propeptide, and the GH-2000 score to the administration of rhIGF-I/rhIGF binding protein-3 complex. The Journal of Clinical Endocrinology and Metabolism, 99(6), 2259-68. https://doi.org/10.1210/jc.2013-3897
Guha N, et al. Biochemical Markers of Insulin-like Growth factor-I Misuse in Athletes: the Response of Serum IGF-I, Procollagen Type III Amino-terminal Propeptide, and the GH-2000 Score to the Administration of rhIGF-I/rhIGF Binding Protein-3 Complex. J Clin Endocrinol Metab. 2014;99(6):2259-68. PubMed PMID: 24606087.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Biochemical markers of insulin-like growth factor-I misuse in athletes: the response of serum IGF-I, procollagen type III amino-terminal propeptide, and the GH-2000 score to the administration of rhIGF-I/rhIGF binding protein-3 complex. AU - Guha,Nishan, AU - Erotokritou-Mulligan,Ioulietta, AU - Bartlett,Christiaan, AU - Nevitt,Simon P, AU - Francis,Michael, AU - Bassett,E Eryl, AU - Cowan,David A, AU - Sönksen,Peter H, AU - Holt,Richard I G, Y1 - 2014/02/25/ PY - 2014/3/11/entrez PY - 2014/3/13/pubmed PY - 2014/8/13/medline SP - 2259 EP - 68 JF - The Journal of clinical endocrinology and metabolism JO - J Clin Endocrinol Metab VL - 99 IS - 6 N2 - CONTEXT: The GH-2000 and GH-2004 research groups developed a method for detecting GH misuse in athletes based on the measurement of serum IGF-I and procollagen type III amino-terminal propeptide (P-III-NP). There are reports that IGF-I is also misused by athletes, but currently there is no internationally recognized test designed to detect recombinant human IGF-I misuse. OBJECTIVE: The objective of the study was to examine the response of serum IGF-I, P-III-NP, and the GH-2000 score to recombinant human (rh) IGF-I/rhIGF binding protein-3 (IGFBP-3) administration in recreational athletes. DESIGN AND SETTING: This was a randomized, double-blind, placebo-controlled rhIGF-I/rhIGFBP-3 administration study at Southampton General Hospital (Southampton, United Kingdom). PARTICIPANTS: Fifty-six recreational athletes (26 women, 30 men) participated in the study. INTERVENTION: Participants were randomized to treatment with low-dose (30 mg/d) or high-dose (60 mg/d) rhIGF-I/rhIGFBP-3 complex or placebo for 28 days. Blood was collected throughout the drug administration and washout periods. Serum IGF-I and P-III-NP were measured using commercial immunoassays and GH-2000 scores were calculated. RESULTS: IGF-I, P-III-NP, and the GH-2000 score rose in response to both low- and high-dose rhIGF-I/rhIGFBP-3 administration. The relative maximum response of IGF-I (approximately 4-fold increase in women and men) was greater than that of P-III-NP (40%-50% increase in women, 35%-50% increase in men). The GH-2000 formulae, which incorporate IGF-I and P-III-NP results, detected up to 61% of women and 80% of men in the rhIGF-I/rhIGFBP-3 groups but, using IGF-I concentrations alone, the sensitivity increased to 94% in both women and men during the administration period. CONCLUSIONS: The rise in P-III-NP after rhIGF-I/rhIGFBP-3 administration is small compared with that after rhGH administration. Although rhIGF-I/rhIGFBP-3 administration can be detected using the GH-2000 score method, a test based on serum IGF-I alone provides better sensitivity. SN - 1945-7197 UR - https://www.unboundmedicine.com/medline/citation/24606087/Biochemical_markers_of_insulin_like_growth_factor_I_misuse_in_athletes:_the_response_of_serum_IGF_I_procollagen_type_III_amino_terminal_propeptide_and_the_GH_2000_score_to_the_administration_of_rhIGF_I/rhIGF_binding_protein_3_complex_ L2 - https://academic.oup.com/jcem/article-lookup/doi/10.1210/jc.2013-3897 DB - PRIME DP - Unbound Medicine ER -